Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

A new strategy capable of directly killing cancer cells and concurrently boosting anti-tumor immunity for the effective treatment of triple-negative breast cancer

EF 2022-23

Résumé
Breast cancer remains a leading cause of death in women in the world. Triple negative breast cancer (TNBC) accounts for only 15-20% of all breast cancers but disproportionately accounts for the majority of breast cancer related deaths. TNBC patients are prone to recurrence between their first and third years post-treatment with the majority of deaths happening within the first five years post-therapy. Chemotherapy is currently the mainstay of systemic medical treatment for TNBC, which is associated with rapid drug-resistance, enrichment of cancer stem cells (CSCs), and disease recurrence. Two CSC subtypes have recently been shown to coexist and both exhibit strong tumor regeneration capacity. Using multiple methods, we have recently observed that two specific signaling pathways must be co-inhibited in the presence of a chemotherapeutic drug to kill bulk cancer cells and suppress both CSC subtypes. Concurrently, the dual inhibition also promotes anti-cancer immunity. The goal of this proposed work is to study the cooperative roles of this new combination therapy, to develop novel, clinically translatable nano-therapeutics, and to evaluate their efficacy in clinically relevant animal models. It is expected that completion of this proposed work will lead to a new and tangible approach to effectively treat TNBC to reduce disease relapse.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
486387
Name
Kirkby Melanie D
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A new strategy capable of directly killing cancer cells and concurrently boosting anti-tumor immunity for the effective treatment of triple-negative breast cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Stem Cells; Immunotherapy; Nanomedicine; Triple-Negative Breast Cancer
Abstract
Breast cancer remains a leading cause of death in women in the world. Triple negative breast cancer (TNBC) accounts for only 15-20% of all breast cancers but disproportionately accounts for the majority of breast cancer related deaths. TNBC patients are prone to recurrence between their first and third years post-treatment with the majority of deaths happening within the first five years post-therapy. Chemotherapy is currently the mainstay of systemic medical treatment for TNBC, which is associated with rapid drug-resistance, enrichment of cancer stem cells (CSCs), and disease recurrence. Two CSC subtypes have recently been shown to coexist and both exhibit strong tumor regeneration capacity. Using multiple methods, we have recently observed that two specific signaling pathways must be co-inhibited in the presence of a chemotherapeutic drug to kill bulk cancer cells and suppress both CSC subtypes. Concurrently, the dual inhibition also promotes anti-cancer immunity. The goal of this proposed work is to study the cooperative roles of this new combination therapy, to develop novel, clinically translatable nano-therapeutics, and to evaluate their efficacy in clinically relevant animal models. It is expected that completion of this proposed work will lead to a new and tangible approach to effectively treat TNBC to reduce disease relapse.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kirkby, Melanie D
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~